Avalyn Pharma Inc. Accounts Payable
Avalyn Pharma Inc. (AVLN) had Accounts Payable of $2.65 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-12
- 2026-06-30: Accounts Payable, Current $2.65M.
- 2026-03-31: Accounts Payable, Current $3.15M.
- 2025-12-31: Accounts Payable, Current $3.76M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $2.65M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $3.15M 10-Q · filed 2026-06-03 |
| 2025-12-31 | $3.76M 10-Q · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B |